Early bactericidal activity of rifabutin versus that of placebo in treatment of disseminated Mycobacterium avium complex bacteremia in AIDS patients

B Dautzenberg, P Castellani, J L Pellegrin, D Vittecoq, C Truffot-Pernot, N Pirotta, D Sassella, B Dautzenberg, P Castellani, J L Pellegrin, D Vittecoq, C Truffot-Pernot, N Pirotta, D Sassella

Abstract

Rifabutin, 600 mg/day, was compared with a placebo in the early treatment of culture-proven Mycobacterium avium bacteremia in patients with AIDS. Following 14 days' treatment, bacteriological success, defined as a negative culture or a reduction in the number of CFU of M. avium organisms per milliliter of blood by a factor of > or = 0.5 log from the baseline, was observed in 7 of 10 (70%) evaluable rifabutin patients and in 1 of 13 (8%) evaluable placebo patients (P = 0.002). Rifabutin is active against M. avium as a single agent and can make a significant contribution to combination regimens for the treatment of disseminated M. avium infection in AIDS patients.

References

    1. Clin Infect Dis. 1993 Jul;17(1):7-20
    1. N Engl J Med. 1993 Sep 16;329(12):898-904
    1. Tubercle. 1987 Sep;68(3):177-82
    1. Tubercle. 1988 Sep;69(3):187-92
    1. J Infect Dis. 1994 Jul;170(1):157-64
    1. J Infect Dis. 1994 Sep;170(3):578-84
    1. Ann Intern Med. 1994 Dec 15;121(12):905-11
    1. J Infect Dis. 1991 Jun;163(6):1326-35
    1. Am Rev Respir Dis. 1991 Sep;144(3 Pt 1):557-9
    1. Am Rev Respir Dis. 1991 Sep;144(3 Pt 1):564-9
    1. Tubercle. 1991 Sep;72(3):168-75
    1. J Infect Dis. 1992 Jun;165(6):1082-5
    1. Clin Infect Dis. 1994 Jul;19(1):84-6
    1. J Infect Dis. 1990 Apr;161(4):801-5

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel